Article
Chemistry, Medicinal
Chaofan Wang, Jie Li, Lingzhi Qu, Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, ZhengChao Tu, Yongheng Chen, Zhang Zhang, Xiaoyun Lu
Summary: MET alterations are crucial in NSCLC and gastric cancers. We designed and optimized a series of new c-Met inhibitors using molecular hybridization and macrocyclization strategy, among which D6808 exhibited potent inhibitory activity, extraordinary target specificity, and promise for further anticancer drug development.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Vipul Bhardwaj, Yan Qin Tan, Ming Ming Wu, Lan Ma, Tao Zhu, Peter E. Lobie, Vijay Pandey
Summary: Nearly 70% of ovarian cancer patients experience recurrence within the first 2 years after initial treatment. Emerging evidence suggests that long non-coding RNAs play a pivotal role in OC progression, therapy resistance and recurrent OC. Studies have reported differential expression patterns of lncRNAs in OC, which are related to increased invasion, metastasis and drug resistance.
Article
Biochemistry & Molecular Biology
Po-Ming Chen, Chui-Nguk Wong, Chui-Na Wong, Pei-Yi Chu
Summary: Ovarian cancer has a high mortality rate and lacks effective targeted therapy. This study aimed to explore genetic markers and their clinical value in ovarian cancer development. 11 genetic markers, including ACTL6A, were found to be significantly elevated in invasive and chemoresistant ovarian cancer. ACTL6A expression was correlated with survival prognosis, and HER2 inhibitor CP724714 showed potential therapeutic benefits in high ACTL6A expression cases. High ACTL6A expression can serve as a biomarker for predicting treatment-refractory, metastasis, and prognosis of ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Elina A. Pietilae, Jordi Gonzalez-Molina, Lidia Moyano-Galceran, Sanaz Jamalzadeh, Kaiyang Zhang, Laura Lehtinen, S. Pauliina Turunen, Tomas A. Martins, Okan Gultekin, Tarja Lamminen, Katja Kaipio, Ulrika Joneborg, Johanna Hynninen, Sakari Hietanen, Seija Grenman, Rainer Lehtonen, Sampsa Hautaniemi, Olli Carpen, Joseph W. Carlson, Kaisa Lehti
Summary: The study reveals that platinum chemotherapy enhances resistance by changing cancer cell adhesion signaling and ECM. The heterogeneity of fibrotic ECM in primary tumors and metastatic sites of HGSC before and after chemotherapy provides insights into cancer aggressiveness and potential treatment strategies. The upregulation of COL6 in metastatic HGSCs post-chemotherapy contributes to resistance and relapse, highlighting the importance of targeting the ECM pathway for therapeutic intervention.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, Research & Experimental
Qinhao Guo, Yong Wu, Xueqi Guo, Lijie Cao, Fei Xu, Haiyun Zhao, Jun Zhu, Hao Wen, Xingzhu Ju, Xiaohua Wu
Summary: This study identified downregulation of CELF2 in ovarian cancer, which correlated with patient survival and affected cell proliferation and metastasis through regulation of FAM198B and the MAPK/ERK signaling pathway. Additionally, curcumin-induced increase in CELF2 expression enhanced ovarian cancer cell sensitivity to cisplatin, providing potential therapeutic targets for ovarian cancer.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)
Article
Cell Biology
Ji Eun Kwon, Yeonsue Jang, Bo Seong Yun, Suki Kang, Yon Hee Kim, Baek Gil Kim, Nam Hoon Cho
Summary: Co-expression of CD24 and MET is associated with poor patient survival and resistance to platinum-based chemotherapy in ovarian cancer. CD24 downregulates miR-181a expression through Src-mediated YY1 activation, leading to increased expression of MET. Silencing of CD24 or MET or overexpression of miR-181a inhibits the manifestation of CSC phenotypes in ovarian cancer cells.
CELL PROLIFERATION
(2023)
Article
Biochemistry & Molecular Biology
Yazmin Brown, Susan Hua, Pradeep S. Tanwar
Summary: High-grade serous ovarian cancer (HGSOC) is a deadly gynaecological cancer with insidious progression. It is now widely accepted that HGSOC originates from the fallopian tube epithelium. This review explores the involvement of the extracellular matrix (ECM) in HGSOC development, including its role in tumourigenesis, metastasis, and drug resistance.
Article
Biochemistry & Molecular Biology
Yun Li, Jingjing Zhang, Ying Cai, Hua Liu, Wen Yang, Yingjie Xu, Masha Huang
Summary: In this study, VSTM2L was identified as a crucial gene associated with ovarian cancer (OC) metastasis, progression, and prognosis. Further experiments showed that silencing VSTM2L increased cell death and inhibited spheroid formation in SKOV3 cells. Mechanistically, VSTM2L was found to be involved in EMT-related TGF-beta and NF-kappa B signaling pathways. These findings highlight VSTM2L as a novel biomarker for OC metastasis and prognosis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Biotechnology & Applied Microbiology
Abdus Subhan, Sara Aly Attia, Vladimir Torchilin
Summary: Metastasis is a major challenge in cancer therapy, and while siRNA therapeutics show promise in treatment, they may not be sufficient on their own. Combining siRNA with targeting agents or small molecule drugs can enhance therapeutic effectiveness in controlling metastasis.
Article
Oncology
Baiyao Wang, Wei Liu, Chunshan Liu, Kunpeng Du, Zhaoze Guo, Guoqian Zhang, Zhong Huang, Shuhui Lin, Bohong Cen, Yunhong Tian, Yawei Yuan, Junguo Bu
Summary: This study investigated the role of cancer-associated fibroblasts (CAFs) in the radiosensitivity of breast cancer cells. The researchers found that CAFs secrete HGF to activate the c-Met signaling pathway, promoting epithelial-to-mesenchymal transition, growth, and radioresistance of breast cancer cells. Radiation was also observed to enhance HGF secretion by CAFs and increase c-Met expression in breast cancer cells, leading to the activation of the HGF/c-Met signaling pathway.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Multidisciplinary Sciences
Biswajit Saha, Tanmay Mathur, James J. Tronolone, Mithil Chokshi, Giriraj K. Lokhande, Amirali Selahi, Akhilesh K. Gaharwar, Vahid Afshar-Kharghan, Anil K. Sood, Gang Bao, Abhishek Jain
Summary: Platelets play a crucial role in the tumor microenvironment, and inhibiting the interaction between platelets and tumor cells may be an effective cancer treatment strategy. Using an ovarian tumor microenvironment chip (OTME-Chip), it was revealed that platelets and tumors interact through GPVI and tumor galectin-3, and inhibiting GPVI could reduce metastatic potential and enhance chemotherapy efficacy. Leveraging the findings from this study, the OTME-Chip could be utilized to explore other vascular and hematological targets in cancer research.
Article
Oncology
Soichiro Mori, Hirofumi Akita, Shogo Kobayashi, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Takehiro Noda, Kunihito Gotoh, Yutaka Takeda, Masahiro Tanemura, Yuichiro Doki, Hidetoshi Eguchi
Summary: Radiation therapy can induce increased c-Met expression in pancreatic cancer cells, leading to enhanced invasion and migration ability, promoting the risk of distant metastasis. Inhibiting c-Met can reverse this enhanced malignant potential.
Review
Oncology
Shuangshuang Mei, Xing Chen, Kai Wang, Yuxin Chen
Summary: Ovarian cancer is a common gynecological malignancy with high morbidity and mortality. Peritoneal metastasis is common in ovarian cancer, involving large amounts of ascites. The mechanism behind this is still unclear.
CANCER CELL INTERNATIONAL
(2023)
Review
Pharmacology & Pharmacy
Chenxi Wang, Chenxi Yu, Hongkai Chang, Jiaqi Song, Shuai Zhang, Jianguo Zhao, Jiyan Wang, Tao Wang, Qi Qi, Changliang Shan
Summary: This review summarizes the role of glucose-6-phosphate dehydrogenase (G6PD) in the progression, metastasis, and chemoresistance of ovarian cancer (OC), and proposes potential molecular mechanisms, providing a systematic understanding of targeting G6PD for the treatment of OC patients.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2023)
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
